PTSD

CRO

Emyria, PsychoGenics team for neuropsychiatric drug trials

Emyria and CRO PsychoGenics have agreed to a collaboration that could accelerate novel MDMA-inspired drug candidates.
Joseph Keenan Sep 21, 2022 5:00am

Aptinyx pauses phase 2 trial of higher dose PTSD med

Apr 20, 2022 1:08pm

Psychedelics inch toward approval, but market may not be ready

Aug 17, 2021 10:40am

Palo Santo launches with $35M to support psychedelics companies

Jul 15, 2021 9:57am

FDA clears Apple Watch sleep app that interrupts nightmares

Nov 10, 2020 10:00am

Aptinyx posts phase 2 PTSD win 2 years after diabetes pain flop

Oct 20, 2020 7:17am